rudolfwu on ARiva:
"Speech and counter-speech do not help here.
The comments made by Bubby are good, but what does that say: facts, facts, and nothing but facts are important.
These are clear, it is not negative.
As I said, a balance would be needed. Disclosure of the facts.
The debt burden is stated as 240 million. Where are the 30 million Facility hidden from Aug. 2019? Based on the 3 quarterly reports for 2019, there is a loss of nearly 60 million. Where is this amount priced in? What about the accrued interest? Questions about questions.
I have spoken of a production of about 25,000 t of copper cathodes in order to be able to cover costs. When I think about it, I'm very naive for that. To service the interest charges alone, it requires a production of approx. 5,000 t of copper cathodes.
- From 30,000 t of copper cathodes per year, m. E. only reached the profit zone. Then, however, the question arises, which part of it deduces in the debt settlement.
So, now a successful week; due to lack of data, we will not be able to shed light on the speculative area."
TG
- Forums
- ASX - By Stock
- TGS
- Ann: Quarterly Activities Report
Ann: Quarterly Activities Report, page-8
-
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TGS (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, CEO / Non-Exec Director
James Graham / Dr Alan Dunton
CEO / Non-Exec Director
SPONSORED BY The Market Online